BioCentury | May 30, 2020
Politics, Policy & Law

Trump abandons WHO, strikes out at China with isolationist policies

After months of blaming China and the World Health Organization for the scope and severity of the COVID-19 pandemic, President Donald Trump lashed out at both again Friday with a trio of policies that could...
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BioCentury | Oct 26, 2018
Clinical News

Castle Creek discontinues Phase II of epidermolysis bullosa compound

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Aug 11, 2017
Clinical News

FDA issues CRL to NDA for Vernalis' CCP-08

Vernalis plc (LSE:VER) said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued in April for its other cough and cold candidate...
BioCentury | Aug 7, 2017
Company News

Vernalis gets another CRL in cough and cold pipeline

Vernalis plc (LSE:VER) lost 2p (11%) to 17p Monday after it said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued in...
BioCentury | Jul 14, 2017
Clinical News

Castle Creek begins Phase II/III of topical diacerein to treat epidermolysis bullosa simplex

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Jul 7, 2017
Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
BioCentury | Apr 26, 2017
Clinical News

CCP-07 regulatory update

FDA issued a complete response letter to an NDA from Vernalis for CCP-07 to treat cough and cold. The company said the CRL did not identify issues with the candidate's formulation or pharmacokinetic profile, but...
Items per page:
1 - 10 of 53